GSK Plc ADR (GSK) concluded trading on Thursday at a closing price of $40.00, with 5.05 million shares of worth about $201.92 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 17.79% during that period and on May 29, 2025 the price saw a gain of about 2.09%. Currently the company’s common shares owned by public are about 2.04B shares, out of which, 2.03B shares are available for trading.
Stock saw a price change of 3.79% in past 5 days and over the past one month there was a price change of 2.64%. Year-to-date (YTD), GSK shares are showing a performance of 18.27% which decreased to -11.35% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $31.72 but also hit the highest price of $45.01 during that period. The average intraday trading volume for GSK Plc ADR shares is 5.47 million. The stock is currently trading 5.11% above its 20-day simple moving average (SMA20), while that difference is up 6.52% for SMA50 and it goes to 6.53% higher than SMA200.
GSK Plc ADR (NYSE: GSK) currently have 2.04B outstanding shares and institutions hold larger chunk of about 18.13% of that.
The stock has a current market capitalization of $81.04B and its 3Y-monthly beta is at 0.50. PE ratio of stock for trailing 12 months is 20.77, while it has posted earnings per share of $1.93 in the same period. Its PEG reads 2.32 and has Quick Ratio of 0.58 while making debt-to-equity ratio of 1.30. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for GSK, volatility over the week remained 1.56% while standing at 1.79% over the month.
Stock’s fiscal year EPS is expected to rise by 8.38% while it is estimated to increase by 11.69% in next year. EPS is likely to grow at an annualized rate of 8.94% for next 5-years, compared to annual growth of -11.63% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Exane BNP Paribas on April 15, 2025 offering a Neutral rating for the stock and assigned a target price of $35.25 to it. On November 15, 2024, Deutsche Bank Downgrade their recommendations, while on November 12, 2024, Jefferies Downgrade their ratings for the stock with a price target of $39.50. Stock get a Neutral rating from Guggenheim on October 31, 2024.
